Results 51 to 60 of about 4,420 (152)

Characterization of ANGPTL3 Deficiency and Molecular Mechanisms of ANGPTL3 Deficiency-induced Hypolipidemia [PDF]

open access: yes, 2018
Johdanto: Väitöstyön tarkoituksena oli tutkia ANGPTL3 puutoksen aiheuttamia muutoksia ihmisessä rasva-aineenvaihdunnan osalta kliinisesti, populaatiotasolla sekä solutasolla.
Tikka, Anna
core  

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion1[S]

open access: yesJournal of Lipid Research, 2015
Humans and mice lacking angiopoietin-like protein 3 (ANGPTL3) have pan-hypolipidemia. ANGPTL3 inhibits two intravascular lipases, LPL and endothelial lipase, and the low plasma TG and HDL-cholesterol levels in ANGPTL3 deficiency reflect increased ...
Yan Wang   +5 more
doaj   +1 more source

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

ANGPTL3 is a novel HDL component that regulates HDL function

open access: yesJournal of Translational Medicine
Background Angiopoietin-like protein 3 (ANGPTL3) is secreted by hepatocytes and inhibits lipoprotein lipase and endothelial lipase activity. Previous studies reported the correlation between plasma ANGPTL3 levels and high-density lipoprotein (HDL ...
Longyan Yang   +12 more
doaj   +1 more source

Senotherapeutics for Knee Osteoarthritis

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman   +6 more
wiley   +1 more source

Differential Roles for IL‐4Rα and IL‐13Rα1 in Immune Cell Infiltration and Epithelial Remodeling in Experimental Eosinophilic Gastritis

open access: yesAllergy, EarlyView.
This study described the development of an experimental model for eosinophilic gastritis (EoG). Experimental EoG recapitulates histopathological features of human disease. including foveolar elongation, fibrosis, eosinophilia, mastocytosis and shared transcriptional programs.
Anish Dsilva   +7 more
wiley   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest   +3 more
wiley   +1 more source

Serum Angiopoietin-like Protein 3 Levels Are Associated with Endothelial Function in Patients with Maintenance Hemodialysis

open access: yesLife, 2023
Angiopoietin-like protein 3 (ANGPTL3) plays an important role in lipid and lipoprotein trafficking and metabolism and is positively correlated with cardiovascular disease.
Tzu-Chiang Wu   +4 more
doaj   +1 more source

Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials and Methods Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials.
Giacomo Ruotolo   +13 more
wiley   +1 more source

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

open access: yes, 2022
Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that in patients with heterozygous FH.
Weronika Adach   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy